What is Aventiv Research?
Founded in 2007 by Dr. Samir Arora, Aventiv Research operates as a specialized clinical research organization (CRO) that facilitates the development of novel medicines through rigorous testing and data-driven methodologies. With a footprint spanning four independent research sites across two states, the company has successfully executed over 450 clinical trials. Its market position is defined by a dual-focus model: providing pharmaceutical sponsors with high-fidelity data while ensuring patient-centric care. The firm's track record includes contributing to the FDA approval of 16 distinct drugs, a testament to its operational excellence and adherence to stringent regulatory standards in the pharmaceutical and diagnostic sectors.
How much funding has Aventiv Research raised?
Aventiv Research has raised a total of $871K across 2 funding rounds:
Debt
$350K
Debt
$521K
Debt (2020): $350K with participation from PPP
Debt (2021): $521K led by PPP
Key Investors in Aventiv Research
PPP
Public-Private Partnership
What's next for Aventiv Research?
With the recent influx of capital, Aventiv Research is well-positioned to accelerate its expansion strategy, likely focusing on the integration of proprietary systems to further optimize trial efficiency. As the company transitions into its next phase of growth, the focus will remain on scaling its therapeutic reach and enhancing its technological infrastructure to meet the evolving demands of global pharmaceutical sponsors. By prioritizing resourcefulness and professional integrity, Aventiv is poised to maintain its competitive edge in the high-stakes environment of clinical research, potentially exploring new therapeutic areas and expanding its site network to capture a larger share of the clinical trial market.
See full Aventiv Research company page
